Active substanceXantinol nicotinateXantinol nicotinate
Similar drugsTo uncover
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Xantinol nicotinate
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Xanthinal nicotinate-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Dosage form: & nbsppills
    Composition:

    For one tablet:

    active substance: xanthinal nicotinate - 150 mg;

    Excipients: lactose monohydrate - 15.7 mg, potato starch 51.3 mg, calcium stearate 2.3 mg, povidone K17 10.7 mg.

    Description:

    Tablets are white or almost white in color, flat-cylindrical, with a facet and a risk.

    Pharmacotherapeutic group:Vasodilating agent
    ATX: & nbsp

    C.04.A.D.02   Xantinol nicotinate

    Pharmacodynamics:

    Combines the properties of the substances of the theophylline and nicotinic acid group: dilates peripheral vessels, improves collateral circulation, enhances oxidative phosphorylation and synthesis of adenosine triphosphate.By reducing peripheral resistance and increasing myocardial contraction, the drug contributes to an increase in the minute volume of blood. Xantinol nicotinate enhances cerebral circulation and reduces the severity of cerebral hypoxia.

    Indications:Is used in adults with obliterating atherosclerosis of the lower extremities, Raynaud's disease, diabetic angiopathy, acute thrombophlebitis of superficial and deep veins and postthrombophlebitic syndrome, trophic ulcers of the lower limbs, pressure ulcers, migraine syndrome Mepera at dermatoses associated with the disorder trophism vascular nature.
    Contraindications:

    Hypersensitivity, acute decompensated heart failure or chronic heart failure, acute myocardial infarction, left stenosis predserdno- ventricular holes, hypotension, hypertension granzitornaya, bleeding, pregnancy (I term), an acute stage of gastric ulcer and duodenal ulcer, acute renal failure, glaucoma.

    Lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

    Children under 18 years.

    Pregnancy and lactation:Do not use in the first trimester of pregnancy. In the II and III trimesters of pregnancy apply only if the intended benefit to the mother exceeds the potential risk to the fetus. Do not use during breastfeeding.
    Dosing and Administration:

    Assign to adults, starting with 150 mg 3 times a day; if necessary, increase the dose to 300-600 mg 3 times a day. Tablets are taken after meals without chewing. As the patient's condition improves, the dose is reduced to 150 mg 2-3 times a day. The course of treatment usually lasts at least 2 months.

    In acute disorders of the blood supply of tissues, the drug is administered parenterally with simultaneous administration of 300 mg (2 tablets) 3 times a day.

    Side effects:

    Reduced blood pressure, weakness, dizziness, nausea, diarrhea, decreased appetite. gastralgia. With long-term administration in high doses, a change in glucose tolerance, an increase in the activity of "liver" transaminases and alkaline phosphatase, hyperuricemia.

    There may be a feeling of heat, tingling and redness of the upper body, especially the neck and head - these symptoms usually disappear after 10-20 minutes, do not require special treatment and are not a contraindication for continuing treatment with the drug.It is necessary to warn the patient before starting treatment.

    If side effects occur that are not listed in the instructions, then the physician should be informed.

    Overdose:Acute overdose can be manifested by arterial hypotension, abdominal pain and vomiting. When an overdose of the drug prescribed symptomatic therapy.
    Interaction:

    Caution should be exercised with the simultaneous administration of xanthinal nicotinate and antihypertensive medications (possibly a sharp increase in their effect).

    Do not use together with monoamine oxidase inhibitors, strophanthin.

    Special instructions:

    With caution appoint patients with labile arterial pressure, with the simultaneous administration of Xanthinal nicotinate and antihypertensive drugs.

    Patients with an implanted pacemaker should be prescribed a lower dose of the drug.

    In patients with diabetes mellitus, Xantinol nicotinate, it should be more often than usual to determine the level of glucose in the blood.

    Effect on the ability to drive transp. cf. and fur:Large doses can cause lower blood pressure and dizziness: apply with extreme caution to vehicle drivers.
    Form release / dosage:

    Tablets 150 mg.

    Packaging:

    For 10 or 20 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil;

    10 tablets per contour non-jawed packaging made of packaging material combined on a paper basis;

    60 tablets per can of polymeric materials;

    6 contour cell packs of 10 tablets, or 3 contour packs of 20 tablets, or 1 can of polymeric materials with instructions for medical use are placed in a pack of cardboard;

    900 contour non-jammed packages or 100 cans with an equal number of instructions for medical use are placed in a group package (for hospitals).

    Storage conditions:Store in a dry, dark place at temperatures above 25 ° C. Keep out of the reach of children.
    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-010612/09
    Date of registration:25.12.2009 / 09.02.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:AVEKSIMA, JSC AVEKSIMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.01.2018
    Illustrated instructions
      Instructions
      Up